BCRX (BioCryst Pharmaceuticals) Quality Rank

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

BioCryst Pharmaceuticals Quality Rank Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie	director	4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin	director	ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244